about
A randomized controlled trial of growth hormone in active pediatric Crohn disease.Otitis Media and Related Complications Among Children with Autism Spectrum Disorders.Hospitalization for Varicella and Zoster in Children with Inflammatory Bowel Disease.Clostridium difficile infection in hospitalized children in the United States.Development of pyloric stenosis after a 4-day course of oral erythromycin.Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in Crohn disease.Hypertension Prevalence, Cardiac Complications, and Antihypertensive Medication Use in Children.Side Effects and Complications of Proton Pump Inhibitors: A Pediatric Perspective.Autism Spectrum Disorders and Metabolic Complications of Obesity.Healthy Late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization.Impact of parents' wartime military deployment and injury on young children's safety and mental health.Bacterial enteritis as a risk factor for childhood intussusception: a retrospective cohort study.Children with Down syndrome are high-risk for severe respiratory syncytial virus disease.Association of prematurity with the development of infantile hypertrophic pyloric stenosis.Magnet ingestions in children presenting to US emergency departments, 2002-2011.Ingesting Self-Grown Produce and Seropositivity for Hepatitis E in the United StatesProspective evaluation of 1-day polyethylene glycol-3350 bowel preparation regimen in childrenVenous thrombotic events in hospitalized children and adolescents with inflammatory bowel diseaseAssociation of Clostridium difficile infections with acid suppression medications in childrenProton Pump Inhibitors in Children: the Good, the Bad, and the Ugly
P50
Q34023206-B71079C0-531A-44F7-8A31-1E1CB778E4CDQ35887571-41299177-DC33-4A44-BD89-7AA9847F4432Q35908973-FC95C662-1072-4A6B-9BFE-8A2396546C6EQ36383006-A04A7A96-A5BD-46AA-BC9C-95806C03047FQ37846744-DB044461-9144-44B6-88DB-14D7E8F40103Q38335822-79ED1B04-4669-49A7-9E4A-D7899A35FCFDQ38414859-0C897312-F2B4-4E7C-88F6-8F6DC913F079Q38593386-A56313E8-048B-49D0-A7D0-17235C3DFDD8Q40510017-2362347A-ED79-4460-99F0-3C3ECEB3B480Q40724372-A4E9A8AA-5A9B-4BA1-AD12-9098A1942F93Q41191591-C2F6C347-543E-48FA-B6C2-0EBF164F97C7Q41435477-A70FAB40-7D13-4819-9FCA-B82058175E05Q41539079-39D442B1-9024-4A99-846C-D03472668A03Q41756327-CEA16704-AAFC-403F-9D25-08DCA0CA8BF8Q51211660-93629E01-F571-4241-BF3F-52F37AFC7A0DQ57002609-B17FAAC0-855D-4D54-8D33-3BA0F0D4F331Q57113942-E6CA8D6A-713F-4552-8972-399CD1C63157Q85645656-3670BC96-7A87-4037-8F83-D978BDCCCA8CQ87547246-00BD9E79-F6ED-4D7E-9543-8024F10C5443Q96307343-C62933CF-816D-4F93-BA65-33BA3BEC9264
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Cade M Nylund
@ast
Cade M Nylund
@en
Cade M Nylund
@es
Cade M Nylund
@nl
type
label
Cade M Nylund
@ast
Cade M Nylund
@en
Cade M Nylund
@es
Cade M Nylund
@nl
prefLabel
Cade M Nylund
@ast
Cade M Nylund
@en
Cade M Nylund
@es
Cade M Nylund
@nl
P106
P31
P496
0000-0003-4543-6804